Continuous Glucose Monitoring (CGM) Sensors Market Size, Share, Growth, and Industry Analysis, By Type (Noninvasive Sensing, Minimally Invasive Sensing), By Application (Home Care, Hospital, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS MARKET OVERVIEW

The global continuous glucose monitoring (CGM) sensors market size stood at USD 8.2 Billion in 2026, growing further to USD 38.75 Billion by 2035 at a CAGR of 18.84% from 2026 to 2035.

The continuous glucose monitoring (CGM) sensors market is transforming diabetes management through real-time glucose tracking, automated alerts, and connected medical devices. Minimally invasive sensing dominates commercially established systems, with most approved wearable sensors using a small filament inserted beneath the skin. The International Diabetes Federation reported that 589 million adults were living with diabetes worldwide in 2024, highlighting substantial demand for improved glucose monitoring.

The United States continuous glucose monitoring (CGM) sensors market benefits from established diabetes care infrastructure, advanced medical technology adoption, and expanding insurance coverage. Healthcare professionals increasingly recommend wearable glucose sensors for patients requiring continuous insight into glucose fluctuations. Abbott and Dexcom maintain strong commercial positions through integrated glucose monitoring platforms, connected applications, and distribution partnerships.

KEY FINDINGS

LATEST TRENDS

The continuous glucose monitoring (CGM) sensors market is experiencing significant technological advancements in wearable biosensors, glucose prediction algorithms, and personalized diabetes management. Manufacturers increasingly emphasize extended sensor longevity, compact device architecture, and convenient mobile connectivity. Abbott's FreeStyle Libre 3 Plus supports a 15-day wear period, demonstrating the industry's focus on reducing replacement frequency. Smartphone applications increasingly display glucose trends, customizable alerts, and historical patterns, helping patients understand how nutrition, physical activity, medication, and sleep influence glucose levels.

Another important trend involves expanding continuous glucose monitoring beyond traditional prescription-based diabetes management. Over-the-counter devices are creating additional opportunities for consumers seeking metabolic health information. Dexcom's Stelo platform reflects growing interest in glucose monitoring for adults who do not use insulin. Meanwhile, artificial intelligence applications are being investigated for predictive alerts, personalized recommendations, and clinical decision support.

MARKET DYNAMICS

DRIVER

Increasing diabetes prevalence and demand for continuous glucose monitoring.

The growing global burden of diabetes represents a major driver of the continuous glucose monitoring (CGM) sensors market. According to the International Diabetes Federation, approximately 589 million adults were living with diabetes worldwide in 2024. This substantial patient population creates demand for accurate glucose tracking, individualized treatment, and improved management of glucose fluctuations. Traditional fingerstick testing provides measurements at specific moments, whereas continuous glucose monitoring sensors generate repeated measurements throughout the day. Healthcare professionals increasingly use glucose trend information to identify nocturnal hypoglycemia, post-meal glucose changes, and treatment effectiveness.

RESTRAINT

Sensor affordability and unequal access to advanced diabetes monitoring.

The continuous glucose monitoring sensors market faces barriers associated with device affordability, recurring replacement requirements, and differences in healthcare reimbursement. Disposable wearable sensors require regular replacement, creating ongoing purchasing obligations for patients and healthcare providers. Although certain products support 15 days of wear, sensor longevity varies according to manufacturer specifications and regulatory authorization. Insurance coverage may depend on diabetes diagnosis, insulin treatment, documented clinical requirements, and national healthcare policies. Patients without comprehensive reimbursement may continue using conventional glucose meters despite the advantages of continuous monitoring.

Expanding connected home healthcare and personalized metabolic monitoring.

Opportunity

Connected healthcare platforms present important opportunities for the continuous glucose monitoring (CGM) sensors market. Home-based diabetes management increasingly incorporates wearable sensors, telehealth consultations, electronic medical records, and automated glucose trend analysis. Continuous monitoring enables healthcare professionals to review patient information remotely and adjust treatment recommendations according to clinical requirements.

Maintaining clinical accuracy, interoperability, and cybersecurity across connected devices.

Challenge

The continuous glucose monitoring sensors market encounters substantial challenges involving measurement accuracy, regulatory compliance, device compatibility, and secure health information management. Continuous glucose monitoring sensors measure glucose in interstitial fluid rather than directly measuring blood glucose, creating potential differences during rapid glucose changes. Manufacturers must validate sensor performance across operating conditions, patient characteristics, and approved wear periods.

•   
•   
  

  Download Free Sample to learn more about this report

    

CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Noninvasive Sensing and Minimally Invasive Sensing.

• Noninvasive Sensing: Noninvasive sensing is assigned a 2% market share in the continuous glucose monitoring (CGM) sensors market, representing an emerging technology category with limited established commercial adoption. Noninvasive glucose monitoring technologies aim to measure glucose without inserting sensors beneath the skin, potentially improving patient comfort and eliminating insertion-related discomfort. Research focuses on optical spectroscopy, electromagnetic sensing, infrared detection, and advanced biosensor technologies. Developers are investigating artificial intelligence algorithms to improve signal interpretation and measurement accuracy. However, differences in skin thickness, hydration, temperature, and physiological characteristics continue to affect performance.

• Minimally Invasive Sensing: Minimally invasive sensing dominates the continuous glucose monitoring (CGM) sensors market with a 98% market share, reflecting the widespread commercial availability of wearable glucose monitoring devices. These systems use small sensor filaments inserted beneath the skin to measure glucose concentrations in interstitial fluid. Leading manufacturers, including Abbott, Dexcom, Medtronic, and Senseonics, provide minimally invasive or implantable continuous glucose monitoring solutions. Increasing demand for real-time glucose tracking, automated alerts, and integration with insulin delivery systems supports adoption. Advanced products offer extended sensor wear, improved accuracy, and smartphone connectivity. Healthcare professionals increasingly recommend continuous glucose monitoring for eligible patients requiring intensive diabetes management. Continued innovation in sensor miniaturization, adhesive technology, and wireless communication strengthens the segment's commercial position.

By Application

Based on Application, the global market can be categorized into Home Care, Hospital, and Others.

• Home Care: Home care dominates the continuous glucose monitoring (CGM) sensors market with a 76% market share, driven by increasing adoption of wearable glucose monitoring devices for personal diabetes management. Continuous glucose monitoring sensors allow patients to track glucose fluctuations throughout daily activities without frequent fingerstick measurements. Smartphone applications provide glucose trends, customizable alerts, and historical monitoring information, supporting informed treatment decisions. Growing awareness of diabetes self-management and remote patient monitoring contributes to home care adoption. Manufacturers are introducing compact sensors with improved wear duration and simplified application procedures. Integration with telemedicine platforms enables healthcare professionals to review patient glucose information remotely. Expanding access to connected healthcare technologies and increasing demand for convenient glucose monitoring continue supporting the home care segment.

• Hospital: The hospital segment accounts for an 18% market share in the continuous glucose monitoring (CGM) sensors market, supported by increasing use of advanced glucose monitoring technologies in clinical settings. Hospitals utilize continuous glucose monitoring for selected patients requiring specialized diabetes management, glucose trend assessment, and treatment optimization. Endocrinology departments and diabetes care specialists evaluate sensor-generated information to identify glucose fluctuations and improve clinical decision-making. Integration with electronic health records and hospital monitoring systems supports coordinated patient care. Healthcare professionals also use continuous glucose monitoring technology during diabetes education and discharge planning. Clinical implementation requires appropriate protocols, staff training, and confirmation of sensor readings when necessary. Increasing interest in digital healthcare and personalized treatment supports further development of hospital applications.

• Others: The others segment represents a 6% market share in the continuous glucose monitoring (CGM) sensors market, covering outpatient clinics, research institutions, diabetes education centers, and selected metabolic health applications. Clinical research organizations utilize continuous glucose monitoring sensors to investigate glucose variability, treatment responses, and physiological changes associated with nutrition and physical activity. Specialized healthcare facilities incorporate wearable glucose monitoring into patient education and preventive healthcare programs. Digital health companies are also exploring glucose monitoring applications for personalized wellness and metabolic awareness. The introduction of over-the-counter glucose monitoring technologies has created additional opportunities outside traditional prescription-based diabetes care. Continued investment in biosensor research, digital platforms, and connected healthcare services may support application diversification.

•   
•   
  Download Free Sample to learn more about this report

    

CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS MARKET REGIONAL INSIGHTS

• North America

North America leads the continuous glucose monitoring (CGM) sensors market with a 42% market share, supported by advanced healthcare infrastructure, established reimbursement systems, and widespread adoption of connected diabetes management technologies. The United States represents the principal regional market, with Abbott, Dexcom, Medtronic, and Senseonics maintaining important commercial operations. Increasing diabetes prevalence and growing awareness of continuous glucose monitoring benefits support adoption among eligible patients. Healthcare providers recommend wearable glucose sensors for personalized treatment, improved glucose trend analysis, and integration with insulin delivery systems.

• Europe

Europe accounts for a 25% market share in the continuous glucose monitoring (CGM) sensors market, supported by established diabetes treatment programs, healthcare reimbursement policies, and increasing adoption of wearable medical devices. Germany, France, the United Kingdom, Italy, and Spain represent important regional markets for continuous glucose monitoring technology. Healthcare providers increasingly incorporate sensor-generated glucose information into diabetes management and personalized treatment planning. Public healthcare systems and specialist diabetes clinics support access to monitoring devices among eligible patients. Abbott, Dexcom, Medtronic, and Senseonics contribute to regional competition through product development and distribution partnerships.

• Asia Pacific

Asia Pacific holds a 24% market share in the continuous glucose monitoring (CGM) sensors market, supported by a substantial diabetes patient population, expanding healthcare infrastructure, and increasing adoption of digital medical technologies. China, India, Japan, South Korea, and Australia represent important regional markets with different healthcare reimbursement and distribution structures. Rising awareness of diabetes complications encourages patients and healthcare professionals to adopt advanced glucose monitoring technologies. Hospitals and specialist diabetes clinics increasingly evaluate wearable sensors for personalized treatment and glucose trend monitoring. Japan and Australia have established continuous glucose monitoring access pathways for eligible patients, while developing healthcare markets face affordability challenges.

• Middle East & Africa

The Middle East & Africa continuous glucose monitoring (CGM) sensors market represents a 5% market share, supported by increasing diabetes awareness, healthcare modernization, and growing demand for advanced medical monitoring technologies. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt are important regional markets for wearable glucose monitoring devices. Healthcare providers increasingly recognize the importance of continuous glucose monitoring in personalized diabetes management and treatment optimization. Government healthcare initiatives and private medical facilities support adoption of connected medical devices in selected countries. However, limited reimbursement coverage, high replacement costs, and uneven healthcare infrastructure restrict widespread accessibility.

• Rest of the World

The Rest of the World segment accounts for a 4% market share in the continuous glucose monitoring (CGM) sensors market, covering Latin America and additional territories outside the principal regional classifications. Brazil, Mexico, Argentina, and Chile represent important markets where diabetes management increasingly incorporates wearable monitoring technologies. Healthcare providers are adopting continuous glucose monitoring systems to support glucose trend assessment, individualized treatment, and patient education. Growing demand for connected medical devices encourages manufacturers to expand distribution partnerships and technical support services. However, affordability, reimbursement limitations, and uneven access to specialist diabetes care remain important barriers.

KEY INDUSTRY PLAYERS

The Continuous Glucose Monitoring (CGM) Sensors Market includes several leading healthcare technology companies focusing on advanced glucose monitoring solutions, sensor accuracy improvement, and real-time diabetes management technologies. Key industry players such as Abbott Laboratories, Dexcom, Medtronic, Senseonics Holdings, and Ascensia Diabetes Care are investing in next-generation CGM sensors, wearable devices, and digital health platforms. These companies are strengthening their market presence through product innovation, improved sensor lifespan, and integration with mobile applications and automated insulin delivery systems.

List of Top Continuous Glucose Monitoring (CGM) Sensors Companies

• Medtronics
• Abbott
• Senseonics
• WaveForm Technologies
• Echo Therapeutics Inc
• Arkal Medical
• Azurite Technologies
• Biorasis
• Calisto Medical
• DexCom Inc
• DirectSens GmbH
• EyeSense GmbH

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the continuous glucose monitoring (CGM) sensors market focuses on biosensor accuracy, extended sensor life, manufacturing efficiency, and connected healthcare platforms. Companies are allocating development resources toward improved electrochemical sensing, predictive algorithms, and automated insulin delivery compatibility. Senseonics' Eversense 365 demonstrates opportunities in long-duration implantable monitoring technology. Investment prospects also include affordable wearable devices, noninvasive sensing research, and localized production for developing healthcare markets. Partnerships involving medical device manufacturers, diabetes clinics, software developers, and distribution networks can accelerate commercialization. Regulatory readiness, clinical evidence, reimbursement access, and cybersecurity capabilities remain essential considerations for investors evaluating glucose monitoring technologies.

NEW PRODUCT DEVELOPMENT

New product development in the continuous glucose monitoring sensors market emphasizes improved sensor longevity, compact wearable designs, accurate glucose measurements, and simplified patient experiences. Dexcom's G7 15 Day system demonstrates progress toward extended wear duration and reduced replacement frequency. Abbott continues developing connected FreeStyle Libre technologies, while Medtronic advances glucose monitoring integration with automated insulin delivery platforms. Senseonics is expanding long-duration implantable sensor capabilities through its Eversense product portfolio. Manufacturers are also investigating alternative sensing materials, advanced adhesives, improved wireless communication, and personalized glucose analytics. Emerging research into noninvasive monitoring may create future opportunities, although clinical accuracy and regulatory validation remain essential.

RECENT DEVELOPMENTS

• April 2025 – Dexcom receives regulatory clearance for extended-wear G7 continuous glucose monitoring technology. Dexcom secured regulatory clearance for its G7 15 Day system, supporting extended sensor wear and improving monitoring convenience for eligible diabetes patients in clinical practice.

• February 2025 – Senseonics submits Eversense 365 for European regulatory assessment and commercialization authorization. Senseonics completed its European regulatory submission for Eversense 365, seeking authorization to expand long-duration implantable glucose monitoring through established regional distribution partnerships and services.

• January 2026 – Sequel MedTech begins commercial integration of automated insulin delivery with implantable monitoring. Sequel MedTech introduced commercial use of its twiist automated insulin delivery system paired with Eversense 365, supporting personalized insulin management through connected glucose measurements.

• June 2026 – Senseonics presents clinical evidence supporting extended performance of implantable glucose monitoring sensors. Senseonics presented real-world Eversense 365 findings involving 12,360 sensors, highlighting sustained monitoring performance, patient adherence, and integration with automated insulin delivery systems in practice.

• June 2026 – Dexcom receives expanded regulatory clearance for Stelo over-the-counter glucose monitoring in children. Dexcom obtained expanded United States clearance for Stelo use among eligible children aged 2 and older, increasing access to glucose monitoring without prescription requirements for noninsulin users.

REPORT COVERAGE

The continuous glucose monitoring (CGM) sensors market report examines technology development, application demand, regional adoption, competitive positioning, and investment opportunities. Coverage includes 2 sensing categories: noninvasive sensing and minimally invasive sensing. Application analysis evaluates home care, hospital, and other healthcare settings, considering patient requirements, clinical adoption, and connected monitoring infrastructure. Regional assessment addresses North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World. Competitive analysis covers established manufacturers, emerging developers, product innovation, regulatory activity, and distribution strategies. The report also evaluates glucose monitoring accuracy, sensor longevity, reimbursement accessibility, interoperability, and opportunities in personalized diabetes management.